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ractional Flow Reserve-Guided
tent Therapy for
ultivessel Disease
aking a Closer Look*
obert J. Applegate, MD
inston-Salem, North Carolina
e are entering an era of percutaneous coronary artery
tenting with unprecedented deliverability, efficacy, and
afety of these devices due in large part to improvements in
econd-generation drug-eluting stents. Although the early
nd late outcomes of coronary stent procedures have been
xtensively evaluated in the past several years, attention has
ocused recently on the selection of patients who would
enefit most from this form of revascularization. The
OURAGE (Clinical Outcomes Utilizing Revasculariza-
ion and Aggressive Drug Evaluation) study indicated that
evascularization could be safely deferred in patients with
hronic stable angina on an optimal medical regimen (1).
ppropriateness criteria have been published that outline
he clinical situations and lesion types in which percutane-
us coronary intervention would be optimal for patients
ith symptomatic coronary artery disease (CAD) (2). Fi-
ally, the FAME (Fractional Flow Reserve Versus Angiog-
aphy for Multivessel Evaluation) study indicated that
ractional flow reserve (FFR) guidance of coronary artery
tenting in patients with multivessel CAD resulted in a
ower rate of adverse events at 1 year than traditional
ngiography-guided coronary artery stenting (3).
See page 2816
The FAME study has created tremendous buzz and
nterest within the cardiology community, particularly
mong interventionalists. This should not be surprising
ecause the results challenge the long-held belief that the
dye don’t lie” (i.e., that optimal stent outcomes are based
n angiographic assessment of lesion morphology and
everity). Discussions of how the FAME study should
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
From the Section of Cardiology, Wake Forest University School of Medicine,1
inston-Salem, North Carolina. Dr. Applegate has received an honorarium from
nd is on the advisory board of Abbott Vascular.hange current practice have been numerous, occurring at
very level of practice from societies down to individual
ractitioners. The context in which the FAME study will be
nterpreted, however, will likely emerge from discussions
eld on the local level. Important considerations in these
iscussions will be answers to questions concerning the
eproducibility and generalizability of the FAME study
esults. Will the results be confirmed by other studies? Can
e use the FAME study to identify angiographic and FFR
ubsets that might particularly benefit from FFR-guided
tent therapy?
Whether the FAME results will be reproduced in other
tudies remains to be determined. This is an important issue
ecause of the potential implications of transitioning from
ngiography-guided to FFR-guided stent therapy. The
FR has been validated as a metric of ischemia in compar-
son studies with noninvasive methodologies of ischemia
etection. Moreover, the prognostic value of an abnormal
FR (i.e., 0.75 to 0.80) has also been evaluated. The
EFER (Deferral of Percutaneous Coronary Intervention)
nd other small studies using the FFR to guide decision
aking have indicated that stenting of a lesion with an FFR
0.75 to 0.80 can safely be deferred for up to 5 years (4).
hat is unique about the FAME study is that the results
uggest for the first time that stenting of lesions with an
FR 0.80 in the current era may actually be detrimental.
he rationale for this apparent paradox is that although
dverse drug-eluting stent–related events occur uncom-
only, they are more frequent than the rate of events of a
esion managed by optimal medical therapy alone. In
ddition to simply confirming the FAME study results, a
etter understanding of an FFR cutoff (e.g.,0.75 vs. 0.80),
ssessing the FFR value in patients with acute coronary
yndromes, and an economic assessment of widespread FFR
se would substantially strengthen a transition to greater
tilization of FFR.
With respect to identifying subsets of patients who might
enefit most from FFR-guided stent therapy, Tonino et al.
5) in this issue of the Journal provide an in-depth evaluation
f the relationship between angiographic severity and the FFR
n the FFR arm of the FAME study. In the FFR group, 44.1%
ad lesions of 50% to 70% angiographic severity, 37.5% had
esions of 71% to 90% angiographic severity, 14.3% had
esions of 91% to 99% angiographic severity, and 10.6%
ad lesions that were totally occluded (p  NS vs. the
istribution of angiographic lesion severity in the angiography-
uided arm of the study). In those with angiographic 3-vessel
isease (approximately one-fourth of the FFR-guided group),
nly 14% had concordant 3-vessel functional disease (i.e.,
FR 0.80 of all 3 vessels), 43% had functional 2-vessel
isease, 34% had functional 1-vessel disease, and 9% had no
esions with an FFR 0.80. Interestingly, in those with
ngiographic 2-vessel disease, the proportion with func-
ional 2-vessel disease was 43%, whereas 45% had functional
-vessel disease and 12% had no lesions with an FFR

t
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June 22, 2010:2822–4 FFR Versus Angiography0.80. Looked at another way, in the overall FFR arm of
he study, the subgroup with angiographic lesion severity of
0% to 70% had an FFR 0.80 in only 35%, which
ncreased to 80% in the group with angiographic lesion
everity of 71% to 90% and to 96% in the group with
ngiographic severity of 91% to 99%.
Although one could raise concerns about the fact that
nly those in the FFR arm of the FAME study were
valuated in this substudy, important observations can still
e made about the study findings. The poor correlation of
ngiographic and functional measures of lesion severity
bserved in the FAME study might seem disconcerting at
rst glance, but should not be surprising. A large portion of
he apparent discrepancy between angiography- and FFR-
etermined severity can be attributed to the well-recognized
igh interobserver variability in evaluating the severity of
oronary stenoses angiographically alone (6). That the
reatest degree of discordance between FFR and angio-
raphic lesion assessment occurred in the subgroup with the
east extent of angiographic stenosis (i.e., 50% to 70%) is
lso not unexpected because this range of angiographic
everity is associated with the highest degree of interob-
erver variability in angiographic assessment of stenosis
everity. Fortunately, the proportion with an FFR 0.80 in
he FAME study increased dramatically in lesions deemed
o have angiographic severity 71%, albeit 20% of these
esions still were associated with an FFR 0.80.
Considering the results of this FAME substudy in the
ontext of clinical practice, lesions with intermediate angio-
raphic severity of 50% to 70% appear to represent a diverse
ix with respect to ischemia potential, and stenting based
olely on an “oculostenotic” basis may not lead to optimal
utcomes. The extent to which interventionalists currently
erform stenting of lesions with an angiographic severity of
0% to 70% will likely influence the extent to which their
ractice could be altered by shifting to an FFR-guided
trategy. At present, a noninvasive ischemia evaluation is
ften available before catheterization and can help guide
ecision making. However, the usefulness of noninvasive
esting in multivessel disease is problematic and may not
ccurately identify all significant lesions accurately (7). If
ne accepts that the FFR will often be 0.80 and that
tenting a lesion with an FFR 0.80 may be detrimental,
hen it would seem important to assess the FFR in inter-
ediate lesions (i.e., 50% to 70% angiographic severity)
efore stenting. In those lesions with angiographic severity
f 71% to 90%, however, routine use of the FFR will likely
e controversial. Because a great majority of lesions with
his degree of angiographic severity have an FFR 0.80,
outine FFR use to avoid stenting in the 20% who may have
n FFR 0.80 may not be clinically or economically
easonable. Ultimately, further studies will need to be
erformed in those with 71% to 90% angiographic severity
o confirm the outcomes of this FAME substudy and
trengthen the rationale for use of the FFR in this important
atient subset. NIt is also important to place the results of the primary
AME study, and this substudy, in the context of the body
f knowledge that exists concerning outcomes in patients
ith multivessel CAD. Historical evaluations of clinical
utcomes in patients with symptomatic CAD have tradi-
ionally been based on the extent of disease determined
ngiographically. Although those with 3-vessel CAD are
enerally believed to have worse long-term outcomes than
hose with 1- or 2-vessel disease, this clinical impression has
ot been consistently supported in clinical trials. For exam-
le, in the medical arms of coronary artery bypass trials,
here were no discernible differences in clinical outcomes
mong those with 1-, 2-, or 3-vessel CAD treated medically
nless there was concomitant left ventricular dysfunction.
he basis for this apparent paradox is not well understood.
owever, the observations from this FAME substudy
uggest that the extent of functional multivessel disease
annot be extrapolated from angiography alone, and thus
tratification of outcomes based solely on angiographic
etermination of severity may be clinically flawed. What is
issing from this substudy of the FAME study is
nformation about the association between the extent of
ngiography- and FFR-determined lesion severity and
linical outcomes at 1 year. This type of assessment would
rovide important support of the overall FAME study
esults indicating that stent therapy is optimally guided by
etermination of ischemic potential of a lesion and not by
imple angiographic assessment of stenosis severity. More-
ver, it would help identify important subgroups that would
enefit most from FFR-guided stent therapy.
Finally, it is important to fully understand how patients
ere selected for inclusion in the FAME study and whether
hose results can be generalized to all patients with mul-
ivessel disease being considered for percutaneous coronary
ntervention. The results of the COURAGE study (1) and
he FAME study (3), suggesting that revascularization can
e deferred safely, are at odds with the body of literature
ndicating that an early invasive strategy with aggressive
tenting is superior to medical therapy in patients with an
cute coronary syndrome (8). How do we reconcile the
pparently divergent results in these 2 groups of patients
ith symptomatic CAD? The most likely explanation is
hat the 2 strategies evaluated patients with different and
istinct manifestations of CAD: ischemia from flow ob-
truction resulting in chronic angina and plaque rupture
esulting in acute coronary syndromes (9). Patients with
hese different manifestations of CAD (chronic ischemia vs.
cute coronary syndrome) have vastly different short-term
dverse event rates, which should not be construed as
omparing “apples to apples.” Ultimately, further studies
xamining functional assessment of lesions in patients with
nstable angina and non–ST-segment myocardial infarction
re needed to define the role of FFR-guided stenting in
atients with these clinical syndromes, and it cannot be
dvocated for use in this clinical situation at this time.
onetheless, the FAME study, including this more detailed
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FFR Versus Angiography June 22, 2010:2822–4nalysis, provides a strong foundation for moving toward
schemia-directed stent therapy in patients with symptom-
tic CAD.
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